Adma Biologics (ADMA) Non-Current Debt (2012 - 2025)

Adma Biologics' Non-Current Debt history runs 14 years deep, the most recent figure standing at $69.3 million for Q4 2025.

• Quarterly Non-Current Debt fell 4.16% year-over-year to $69.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.3 million (down 4.16% YoY) and the FY2025 annual result came in at $69.3 million, down 4.16% from the prior year.
• Non-Current Debt was $69.3 million for Q4 2025 at Adma Biologics, down from $70.1 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $144.3 million in Q1 2023 and bottomed at $69.3 million in Q4 2025.
• A 5-year average of $110.9 million and a median of $116.0 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt jumped 50.56% — and 2024, when it sank 44.61%.
• Adma Biologics' Non-Current Debt stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then retreated by 8.57% to $130.6 million in 2023, then sank by 44.61% to $72.3 million in 2024, then decreased by 4.16% to $69.3 million in 2025.
• Business Quant data shows ADMA's Non-Current Debt at $69.3 million in Q4 2025, $70.1 million in Q3 2025, and $73.4 million in Q2 2025.